US FDA Likely Cannot Force Sponsors To Fund Opioid Prescribing Guideline Trials
Once the National Academies of Sciences, Engineering and Medicine find conditions needing more evidence to support prescribing guidelines, the agency may have find a way to gather the data.
You may also be interested in...
Amid Hype Over Narcan First Generic, A Plea For A Labeling Change
Naloxone distribution programs ask that the cheaper generic injectable formulation have the same community-use language in its label as the nasal spray and auto-injector so they can maximize their distribution efforts.
Norman Sharpless Will Arrive At US FDA With Many Challenges Awaiting
Outgoing Commissioner Scott Gottlieb will leave his successor a plate full of initiatives, should he choose to continue agency engagement of them.
Long-Term Opioid Efficacy Studies Will Take Years, Gottlieb Says
Trials will be mandated as part of new authority granted by SUPPORT Act and are intended to determine whether opioid efficacy decreases with long-term use.